骨生物製药市场：按同种异体移植、骨形成蛋白、合成移植、脱矿骨基质、陶瓷移植和细胞移植划分 - 全球预测，2025-2032

预计到 2032 年，骨生物製药市场规模将成长至 21.1 亿美元，复合年增长率为 5.64%。

策略介绍，阐述生医材料创新、临床需求压力与采购动态如何融合，重塑骨生物製药

骨生物学已从重组外科的辅助学科发展成为现代整形外科和脊椎护理的核心组成部分。生物材料科学、生物讯号分子和细胞疗法的最新进展共同扩展了外科医生可用的治疗套件，同时医疗保健系统和支付方也越来越要求临床价值和成本效益的证据。在这种环境下，创新者和应用者必须应对相互交织的压力，包括需要证明其改善了患者预后、满足严格的监管审查，并在全球采购受限的情况下实现供应链的可靠性。

因此，相关人员必须协调快速的技术进步与现实的临床应用路径。临床医生评估骨生物製药不仅基于其生物学性能，还基于其处理特性、灭菌方法和储存物流。同时，医院采购团队和整合配送网路优先考虑可预测的定价和精简的采购流程。因此，产品的成功取决于整合临床疗效、操作适用性和报销可行性的多维提案主张。本引言将聚焦在科学创新、临床预期和商业性现实如何共同重塑骨生物製药，以此为后续分析组装。

材料创新、监管严格性和供应链弹性的重大转型正在再形成临床应用和商业策略

骨生物製药领域正在经历一场变革，这不仅反映了技术的成熟度，也反映了系统性医疗保健的迫切需求。新型生物製药和复合材料正在透过改善骨诱导和骨传导特性来重新定义治疗预期，而载体基质和给药方式的不断改进则正在改善手术工作流程和患者復健路径。同时，监管要求也愈发严格，迫使研发人员优先考虑严格的临床终点、真实世界证据产生和严格的生产控制，以满足相对的安全性和有效性标准。

同时，由于全球製造地和原材料供应面临地缘政治和物流压力，供应链弹性变得至关重要。这导致人们对本地生产、替代筹资策略和库存管理的兴趣日益浓厚，以减少手术延误。支付模式也在变化，越来越注重捆绑支付和分期付款，以奖励功能结果的显着改善和再手术率的降低。总而言之，这些发展正在促进材料科学家、临床医生和健康经济学家之间的跨学科合作，重塑产品开发的重点，使其更注重可证明的价值，而不仅仅是新颖性。

评估 2025 年美国关税将如何重塑骨生物製药和医疗保健提供者的采购、定价和供应稳定性

2025年美国加征关税将对整个骨生物製药系产生复杂的商业性和营运影响。关税调整将改变进口零件、成品和製造投入的相对成本结构，影响製造商和经销商的策略采购和定价决策。根据产品类别的不同，进口关税的提高将促使企业重新审视海外生产，并鼓励近岸外包或国内生产，以减轻利润率的侵蚀并平滑前置作业时间的波动。

此外，由于采购团队需要审查采购合约定价并评估植入和生物假体的总拥有成本，医院和门诊手术中心可能会面临下游影响。鑑于典型的合约週期，签订长期合约的供应商可能会经历价格传导延迟，而现货采购商和规模较小的供应商可能会面临更即时的成本压力。作为应对措施，製造商可能会采取各种策略，包括重新谈判合约、选择性地转嫁客製化相关成本，以及有针对性地投资于供应链冗余。重要的是，这些动态有利于能够提供稳定供应和可预测物流的产品和供应商，同时也给严重依赖进口投入的低利润商品带来压力。

细分层面的洞察揭示了物料输送类别、运输方式和细胞采购如何影响临床用例要求和商业化策略

节段层面的动态变化揭示了反映材料特性、临床指征和处理偏好的差异化轨迹。由于储存稳定性和生物完整性之间的权衡，冷冻干燥和鲜冻同种异体移植物在临床使用案例中持续存在差异。冷冻干燥同种异体移植物具有物流优势和更长的库存生命週期，而鲜冻则具有更好的细胞和结构保存效果，可能更受临床医生在某些复杂重组中的偏好。因此，产品定位必须与医院的储存能力和外科医师的偏好相符。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 重组人类骨形成蛋白在复杂脊椎融合手术的应用日益增多
• 合成胜肽增强支架在促进创伤骨再生的进展
• 增加对自体干细胞治疗与生物材料载体结合的整形外科应用的投资
• 用于关节重组手术的具有骨诱导涂层的3D列印多孔钛植入的开发
• 用于微创脊椎增强术的膨胀可注射脱矿骨基质製剂
• 基于奈米技术的新兴磷酸钙水泥，具有可控的降解特性，可用于修復骨缺损
• 学术界和生物技术公司联合研究促进骨形成的基因治疗方法
• 监管部门的核准加速了含有生长因子的下一代牛胶原蛋白基质的商业化
• 合成聚合物陶瓷复合支架在颚颜面和牙骨重组手术的应用日益增多
• 专注于透过开发微生物表现系统生产的重组 BMP 类似物来降低成本

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 骨生物製药市场（依同种异体移植类型）

• 冷冻干燥
• 新鲜冷冻

9. 骨生物製药市场（依骨形成蛋白）

• Bmp-2
• Bmp-7

第 10 章骨生物製药市场（依合成移植）

• 复合材料
• 羟基磷灰石
• 磷酸三钙

第 11 章。骨生物製药市场（按脱矿骨基质）

• 纤维
• 凝胶
• 粉末
• 油灰

第 12 章 骨生物製药市场（依陶瓷移植）

• 生物活性玻璃
• 生物陶瓷

13. 细胞移植骨生物製药市场

• 同种异体
• 自体移植

第 14 章骨生物製药市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第 15 章骨生物製药市场（按类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 16 章骨生物製药市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Medtronic plc
  • Johnson & Johnson
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
  • Baxter International Inc.
  • Globus Medical, Inc.
  • NuVasive, Inc.
  • RTI Surgical, Inc.
  • Orthofix Medical Inc.
  • Exactech, Inc.

The Osteobiologics Market is projected to grow by USD 2.11 billion at a CAGR of 5.64% by 2032.

A strategic introduction framing how biomaterials innovation, clinical demand pressures, and procurement dynamics are converging to reshape the osteobiologics landscape

Osteobiologics has evolved from a niche adjunct in reconstructive surgery into a central component of contemporary orthopedics and spinal care. Recent advances in biomaterials science, biologic signaling molecules, and cell-based therapies have collectively expanded the therapeutic toolkit available to surgeons, while health systems and payers increasingly demand evidence of clinical value and cost-effectiveness. In this environment, innovators and adopters navigate intersecting pressures: the need to demonstrate improved patient outcomes, to satisfy tighter regulatory scrutiny, and to achieve supply chain reliability under global sourcing constraints.

Consequently, stakeholders must reconcile rapid technological progress with pragmatic clinical adoption pathways. Clinicians evaluate osteobiologics not only on biological performance but also on handling characteristics, sterilization modalities, and storage logistics. Meanwhile, hospital purchasing teams and integrated delivery networks prioritize predictable pricing and streamlined procurement. As a result, product success depends on a multidimensional value proposition that integrates clinical efficacy, operational fit, and reimbursement viability. This introduction frames the subsequent analysis by highlighting how scientific innovation, clinical expectations, and commercial realities are converging to reshape the osteobiologics landscape.

Key transformative shifts driven by materials innovation, regulatory rigor, and supply chain resilience reshaping clinical adoption and commercial strategies

The osteobiologics sector is experiencing transformative shifts that reflect both technological maturation and systemic health-care imperatives. Emerging biologic agents and composites are redefining therapeutic expectations by offering improved osteoinductive and osteoconductive profiles, while incremental improvements in carrier matrices and delivery formats have enhanced surgical workflow and patient recovery pathways. At the same time, regulatory pathways have become more prescriptive, prompting developers to prioritize rigorous clinical endpoints, real-world evidence generation, and tighter manufacturing controls to satisfy both safety and comparative effectiveness standards.

Concurrently, supply chain resilience has moved to the forefront as global manufacturing footprints and raw material availability face geopolitical and logistical stressors. This has accelerated interest in localized manufacturing, alternative sourcing strategies, and inventory management practices designed to reduce surgical delays. Payment models are also shifting, with an increased focus on bundled payments and episode-based reimbursement that reward demonstrable improvements in functional outcomes and reduced revision rates. Taken together, these developments are incentivizing cross-disciplinary collaboration between material scientists, clinicians, and health economists, and they are reshaping product development priorities toward demonstrable value over novelty alone.

Assessment of how the 2025 United States tariffs will reconfigure sourcing, pricing, and supply stability across osteobiologics manufacturers and care providers

The imposition of United States tariffs in 2025 introduces a complex layer of commercial and operational consequences across the osteobiologics ecosystem. Tariff adjustments alter the relative cost structures of imported components, finished products, and manufacturing inputs, thereby influencing strategic sourcing and pricing decisions for manufacturers and distributors. For some product families, increased import duties will prompt a reassessment of offshore manufacturing, incentivizing nearshoring or domestic production to mitigate margin erosion and mitigate lead-time volatility.

Moreover, hospitals and ambulatory surgery centers will face downstream implications as procurement teams reprice purchase agreements and evaluate the total cost of ownership for implants and biologic grafts. Given typical contracting cycles, organizations with longer-term agreements may see delayed price transmission, whereas spot purchases and smaller providers could encounter more immediate cost pressure. In response, manufacturers are likely to pursue a mix of strategies: contractual renegotiation, selective pass-through of customs-related costs, and targeted investments in supply chain redundancy. Importantly, these dynamics will favor products and suppliers that can demonstrate stable availability and predictable logistics, while also pressuring lower-margin commodity offerings that rely heavily on imported inputs.

Segment-level insights revealing how material classes, carrier formats, and cell sourcing shape clinical use cases handling requirements and commercialization strategies

Segment-level dynamics reveal differentiated trajectories that reflect material properties, clinical indications, and handling preferences. Based on Allografts, market is studied across Freeze Dried and Fresh Frozen, and these two modalities continue to diverge in clinical use cases because of trade-offs between shelf stability and biological integrity. Freeze-dried allografts offer logistical advantages and longer in-stock lifecycles, whereas fresh frozen variants provide enhanced cellular and structural preservation that clinicians may prefer for certain complex reconstructions. Therefore, product positioning must align with hospital storage capacity and surgeon preferences.

Based on Bone Morphogenetic Protein, market is studied across Bmp-2 and Bmp-7, and these BMP classes retain distinct safety and efficacy profiles that guide clinical selection. Bmp-2 has been widely scrutinized for both strong osteoinductive activity and a profile of reported adverse events in specific contexts, while Bmp-7 presents an alternative signaling approach that some surgeons favor for select indications. Developers must therefore tailor clinical programs and labeling strategies to the risk-benefit expectations of orthopedic and spinal specialists.

Based on Synthetic Grafts, market is studied across Composites, Hydroxyapatite, and Tricalcium Phosphate, and each material class presents unique resorption kinetics and mechanical characteristics. Composites enable hybrid performance characteristics that can be optimized for particular surgical workflows, whereas hydroxyapatite and tricalcium phosphate offer predictable osteoconductivity and resorption behaviors that surgeons leverage according to defect size and load-bearing requirements. Based on Demineralized Bone Matrix, market is studied across Fibers, Gel, Powder, and Putty, and these DBM carriers influence handling, carrier retention at the defect site, and local bioactivity; accordingly, carrier innovation remains a fertile area for differentiation.

Based on Ceramic Grafts, market is studied across Bioactive Glass and Bioceramics, and these materials increasingly appeal to clinicians seeking enhanced bioactivity and controlled degradation. Finally, based on Cell Based Grafts, market is studied across Allogenic and Autologous, and the cell-source distinction continues to drive regulatory complexity, logistics, and cost structures; autologous solutions offer immune-compatibility advantages but require more complex perioperative workflows, while allogenic cell-based platforms favor off-the-shelf convenience at the expense of additional manufacturing and donor screening demands.

Taken together, segmentation insights underscore that therapeutic performance, handling characteristics, and supply logistics jointly determine clinical uptake. Therefore, companies that align innovation with clinician workflow efficiencies and payer-relevant outcomes will be better positioned to secure durable adoption.

Regional dynamics and market access imperatives explaining how regulatory complexity procurement models and clinical practices vary across global healthcare regions

Regional dynamics vary substantially and are driven by differential regulatory frameworks, clinician practice patterns, and payer structures across major economic regions. In the Americas, clinical adoption tends to be influenced by a strong emphasis on evidence-based reimbursement and surgeon-driven preferences, with high procedural volumes in spinal and orthopedic subspecialties that favor products demonstrating clear improvements in fusion rates and recovery times. As a result, manufacturers often prioritize extensive clinical datasets and direct engagement with key opinion leaders in this region to accelerate hospital formulary acceptance.

In Europe, Middle East & Africa, regulatory heterogeneity and varying reimbursement environments create both opportunities and challenges. Some countries within this region maintain centralized procurement systems that favor cost-effective standardized products, while others preserve clinician autonomy that enables faster uptake of differentiated biologics. Market entrants must therefore tailor market access strategies to country-level procurement dynamics and to pockets of clinical innovation that can serve as regional proofs of concept.

In Asia-Pacific, rapid procedural growth, expanding hospital infrastructure, and increasing investment in domestic manufacturing capacity are notable drivers. Surgical volumes in certain countries are rising as orthopedic care becomes more accessible, and local manufacturers are scaling to meet demand, which affects competitive dynamics and pricing pressure. Across all regions, the ability to ensure cold-chain logistics for sensitive allografts or to provide training and support to clinicians performing novel procedures will significantly influence regional success. Consequently, companies that adapt commercial, regulatory, and supply strategies to regional nuances will capture the most durable opportunities.

Competitive positioning and strategic priorities among leading manufacturers revealing how partnerships manufacturing quality and clinical evidence drive sustainable advantage

Leading industry participants demonstrate differing strategic priorities, with some organizations emphasizing platform technologies and scale manufacturing while others focus on niche differentiation through specialized graft formulations or proprietary biologics. A subset of competitors invests heavily in clinical evidence generation and health economics to support favorable formulary positioning and to navigate evolving reimbursement pathways. Conversely, agile smaller firms often concentrate on surgical handling innovations and targeted physician education programs that can accelerate adoption in high-value indications.

Strategic partnerships and licensing deals remain a common mechanism to combine scientific innovation with commercial reach, enabling novel biologic developers to leverage established distribution networks and regulatory expertise. Moreover, manufacturing scale and quality systems are increasingly viewed as competitive advantages; companies that can deliver consistent lot-to-lot performance and transparent supply data secure deeper trust with hospital procurement teams. Intellectual property around carrier matrices and delivery systems continues to be a differentiator, shaping both defensive and offensive strategies in M&A and collaboration discussions. Ultimately, competitive positioning in this sector depends on the alignment of clinical differentiation, regulatory readiness, and supply reliability.

Actionable recommendations for industry leaders balancing innovation supply resilience and evidence generation to secure clinical adoption and commercial sustainability

Industry leaders should adopt a tri-fold approach that balances product innovation, supply chain resilience, and evidence generation to sustain growth and clinical relevance. First, prioritize product portfolios that deliver demonstrable clinical value through improved biological performance and surgeon-centric handling attributes. Investing in carrier optimization and modular delivery systems can enhance intraoperative efficiency, reduce procedure time, and address clinician pain points that frequently determine product selection.

Second, fortify supply chain strategies by evaluating nearshoring opportunities, diversifying suppliers for critical inputs, and implementing robust inventory forecasting tied to procedural volumes. These measures reduce exposure to tariff-related cost shocks and logistical disruptions, while improving on-time delivery metrics that hospitals and surgical centers increasingly require. Third, strengthen clinical and economic evidence through targeted real-world studies and health economic analyses that speak directly to payer concerns around outcomes and cost-effectiveness. By aligning clinical trials and registries with endpoints that matter to payers and providers, companies can better support reimbursement dialogues and formulary inclusion.

Finally, cultivate integrated commercial models that combine surgeon education, outcomes support, and value-based contracting pilots. This holistic approach fosters deeper clinical relationships and accelerates uptake of differentiated products while enabling early identification of barriers to adoption that can be addressed through iterative product and service enhancements.

Methodological approach explaining how clinician interviews regulatory reviews and supply chain consultations were integrated to produce validated strategic insights

This analysis synthesizes primary interviews with clinicians, supply chain leads, and payer advisors, augmented by secondary technical literature and regulatory filings to produce a rigorous, triangulated view of current trends. Clinical insights were gathered through structured discussions with specialists in orthopedic and spinal surgery to capture real-world handling preferences, indication-specific performance considerations, and adoption drivers. Supply chain and procurement perspectives were obtained from hospital purchasing leaders and distribution partners to understand logistics, contracting cycles, and inventory practices.

In addition, the review included a systematic appraisal of recent peer-reviewed studies and regulatory communications to validate product safety profiles, mechanism-of-action claims, and labeling constraints. Data synthesis prioritized cross-validation across sources to reduce bias and to ensure that strategic conclusions reflect both clinical realities and commercial imperatives. Throughout the methodology, emphasis was placed on transparency of assumptions, reproducibility of analytic steps, and sensitivity checks to account for variability in practice patterns across regions and indications. This methodological rigor underpins the recommendations and ensures they are actionable for stakeholders evaluating innovation, market entry, or portfolio optimization.

Concluding synthesis highlighting how clinical validation operational excellence and market access alignment will determine long term success in osteobiologics

In closing, the osteobiologics landscape is characterized by rapid technical evolution coupled with heightened expectations for clinical evidence and supply reliability. Innovations in biologic signaling, composite materials, and carrier systems continue to expand therapeutic possibilities, yet adoption ultimately hinges on integration with clinical workflows and payer-relevant outcomes. Tariff changes and regional procurement variations add layers of commercial complexity that require proactive supply chain and market access strategies. Therefore, companies that combine rigorous clinical validation with operational excellence and adaptive commercial models will lead the next phase of sector growth.

As stakeholders navigate these dynamics, the priority should be to align product development with the pragmatic needs of surgeons, hospitals, and payers, while maintaining manufacturing discipline and evidence-generation commitments. This dual focus will enable more predictable adoption curves and better alignment with value-based care objectives, thereby supporting the sustained translation of scientific advances into improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increasing adoption of recombinant human bone morphogenetic proteins for complex spinal fusion procedures
• 5.2. Advancements in synthetic peptide-enhanced scaffolds for accelerated bone regeneration in trauma cases
• 5.3. Rising investment in autologous stem cell therapies combined with biomaterial carriers for orthopedic applications
• 5.4. Development of 3D printed porous titanium implants with osteoinductive coatings for joint reconstruction surgeries
• 5.5. Expansion of injectable demineralized bone matrix formulations for minimally invasive spinal augmentation techniques
• 5.6. Emergence of nanotechnology-based calcium phosphate cements with controlled degradation profiles for bone defect repair
• 5.7. Collaborative research between academic institutions and biotech firms on gene therapy approaches for enhancing osteogenesis
• 5.8. Regulatory approvals accelerating commercialization of next generation bovine-derived collagen matrices with growth factor incorporation
• 5.9. Increasing use of synthetic polymer-ceramic composite scaffolds in maxillofacial and dental bone reconstruction procedures
• 5.10. Focus on cost reduction through development of recombinant BMP analogs produced in microbial expression systems

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteobiologics Market, by Allografts

• 8.1. Freeze Dried
• 8.2. Fresh Frozen

9. Osteobiologics Market, by Bone Morphogenetic Protein

• 9.1. Bmp-2
• 9.2. Bmp-7

10. Osteobiologics Market, by Synthetic Grafts

• 10.1. Composites
• 10.2. Hydroxyapatite
• 10.3. Tricalcium Phosphate

11. Osteobiologics Market, by Demineralized Bone Matrix

• 11.1. Fibers
• 11.2. Gel
• 11.3. Powder
• 11.4. Putty

12. Osteobiologics Market, by Ceramic Grafts

• 12.1. Bioactive Glass
• 12.2. Bioceramics

13. Osteobiologics Market, by Cell Based Grafts

• 13.1. Allogenic
• 13.2. Autologous

14. Osteobiologics Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Osteobiologics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Osteobiologics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Medtronic plc
  • 17.3.2. Johnson & Johnson
  • 17.3.3. Stryker Corporation
  • 17.3.4. Zimmer Biomet Holdings, Inc.
  • 17.3.5. Baxter International Inc.
  • 17.3.6. Globus Medical, Inc.
  • 17.3.7. NuVasive, Inc.
  • 17.3.8. RTI Surgical, Inc.
  • 17.3.9. Orthofix Medical Inc.
  • 17.3.10. Exactech, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL OSTEOBIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. OSTEOBIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. OSTEOBIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. OSTEOBIOLOGICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL OSTEOBIOLOGICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL OSTEOBIOLOGICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FRESH FROZEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FRESH FROZEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FRESH FROZEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FRESH FROZEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FRESH FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FRESH FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-2, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-2, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-2, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-2, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-2, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-2, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-7, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-7, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-7, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-7, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-7, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BMP-7, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COMPOSITES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COMPOSITES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COMPOSITES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COMPOSITES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COMPOSITES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COMPOSITES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY HYDROXYAPATITE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY HYDROXYAPATITE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY HYDROXYAPATITE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY HYDROXYAPATITE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY HYDROXYAPATITE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY HYDROXYAPATITE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY TRICALCIUM PHOSPHATE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY TRICALCIUM PHOSPHATE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY TRICALCIUM PHOSPHATE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY TRICALCIUM PHOSPHATE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY TRICALCIUM PHOSPHATE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY TRICALCIUM PHOSPHATE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FIBERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FIBERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FIBERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FIBERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FIBERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY FIBERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY PUTTY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY PUTTY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY PUTTY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY PUTTY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY PUTTY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY PUTTY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOACTIVE GLASS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOACTIVE GLASS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOACTIVE GLASS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOACTIVE GLASS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOACTIVE GLASS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOACTIVE GLASS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOCERAMICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOCERAMICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOCERAMICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOCERAMICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOCERAMICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY BIOCERAMICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGENIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGENIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGENIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 111. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 113. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 115. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 117. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 118. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 119. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 120. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 121. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 122. AMERICAS OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 123. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 126. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 127. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 128. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 130. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 131. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 132. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 133. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 134. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 135. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 136. NORTH AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 137. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 140. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 141. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 142. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 143. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 144. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 145. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 146. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 147. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 148. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 150. LATIN AMERICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 179. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 182. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 183. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 184. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 185. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 186. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 187. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 188. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 189. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 190. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 193. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 196. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 197. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 198. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 199. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 200. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 201. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 202. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 203. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 204. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 205. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 206. AFRICA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 207. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 210. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 211. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 212. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 213. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 214. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 215. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 216. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 217. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 218. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 219. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 220. ASIA-PACIFIC OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 226. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 227. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 228. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 229. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 230. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 231. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 232. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 233. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 234. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 235. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 236. ASEAN OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 237. GCC OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. GCC OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. GCC OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 240. GCC OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 241. GCC OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 242. GCC OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 243. GCC OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 244. GCC OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 245. GCC OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 246. GCC OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 247. GCC OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 248. GCC OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 249. GCC OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 250. GCC OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 251. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 254. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 255. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 256. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 257. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 258. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 259. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 260. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 261. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 262. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 263. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 264. EUROPEAN UNION OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 265. BRICS OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. BRICS OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. BRICS OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 268. BRICS OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 269. BRICS OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 270. BRICS OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 271. BRICS OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 272. BRICS OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 273. BRICS OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 274. BRICS OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 275. BRICS OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 276. BRICS OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 277. BRICS OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 278. BRICS OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 279. G7 OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 280. G7 OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 281. G7 OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 282. G7 OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 283. G7 OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 284. G7 OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 285. G7 OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 286. G7 OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 287. G7 OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 288. G7 OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 289. G7 OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 290. G7 OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 291. G7 OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 292. G7 OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 293. NATO OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 294. NATO OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 295. NATO OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 296. NATO OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 297. NATO OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 298. NATO OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 299. NATO OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 300. NATO OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 301. NATO OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 302. NATO OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 303. NATO OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 304. NATO OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 305. NATO OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 306. NATO OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 307. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 308. GLOBAL OSTEOBIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 309. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 310. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 311. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 312. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 313. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 314. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 315. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 316. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 317. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 318. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 319. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 320. UNITED STATES OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 321. CANADA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 322. CANADA OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 323. CANADA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 324. CANADA OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 325. CANADA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 326. CANADA OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 327. CANADA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 328. CANADA OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 329. CANADA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 330. CANADA OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 331. CANADA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 332. CANADA OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 333. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 334. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 335. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 336. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 337. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 338. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY SYNTHETIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 339. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2018-2024 (USD MILLION)
• TABLE 340. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY DEMINERALIZED BONE MATRIX, 2025-2032 (USD MILLION)
• TABLE 341. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2018-2024 (USD MILLION)
• TABLE 342. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY CERAMIC GRAFTS, 2025-2032 (USD MILLION)
• TABLE 343. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2018-2024 (USD MILLION)
• TABLE 344. MEXICO OSTEOBIOLOGICS MARKET SIZE, BY CELL BASED GRAFTS, 2025-2032 (USD MILLION)
• TABLE 345. BRAZIL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2018-2024 (USD MILLION)
• TABLE 346. BRAZIL OSTEOBIOLOGICS MARKET SIZE, BY ALLOGRAFTS, 2025-2032 (USD MILLION)
• TABLE 347. BRAZIL OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2018-2024 (USD MILLION)
• TABLE 348. BRAZIL OSTEOBIOLOGICS MARKET SIZE, BY BONE MORPHOGENETIC PROTEIN, 2025-2032 (USD MILLION)
• TABLE 349. BRAZIL OSTEOBIOLOGICS MARKET SIZ